BeOne Medicines CEO exercises options, sells ADSs
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported both option exercises and share sales.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported both option exercises and share sales. On July 14, 2026 he exercised options covering 1,736,800 ordinary shares and sold 145,861 American Depositary Shares at prices between $302.48 and $307.87 per ADS under a Rule 10b5-1 trading plan. After these transactions he holds 5,445,917 ordinary shares directly, additional indirect interests through trusts and a Roth IRA, and 462,866 remaining share options.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
OYLER JOHN
Role
Chief Executive Officer
Sold
145,861 shs ($44.63M)
Approx. gross sale proceeds
$44.63M
Approx. exercise cost
$7.23M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) F14, F15 | 1,264,666 | $0.00 | $0.00 |
| Exercise | Share Option (Right to Buy) F16, F17 | 472,134 | $0.00 | $0.00 |
| Sale | American Depositary Shares F6, F7, F8 | 4,139 | $303.0687 | $1.25M |
| Sale | American Depositary Shares F6, F7, F9 | 8,122 | $303.9264 | $2.47M |
| Exercise | American Depositary Shares F6 | 97,282 | $36.90 | $3.59M |
| Exercise | American Depositary Shares F6 | 36,318 | $100.04 | $3.63M |
| Sale | American Depositary Shares F6, F7, F10 | 39,090 | $305.0207 | $11.92M |
| Sale | American Depositary Shares F6, F7, F11 | 45,895 | $306.2126 | $14.05M |
| Sale | American Depositary Shares F6, F7, F12 | 40,781 | $306.9349 | $12.52M |
| Sale | American Depositary Shares F6, F7, F13 | 7,834 | $307.5739 | $2.41M |
| Holding | Ordinary Shares | -- | -- | -- |
| Holding | Ordinary Shares F1 | -- | -- | -- |
| Holding | Ordinary Shares F2 | -- | -- | -- |
| Holding | Ordinary Shares F3 | -- | -- | -- |
| Holding | Ordinary Shares F4 | -- | -- | -- |
| Holding | Ordinary Shares F5 | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 462,866 contracts (Direct);
American Depositary Shares — 0 shares (Direct);
Ordinary Shares — 5,445,917 shares (Direct);
Ordinary Shares — 46,031,994 shares (Indirect, See Footnote)
Footnotes (17)
- F1. These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
- F2. These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
- F3. These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
- F4. These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
- F5. These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.
- F6. Each American Depositary Share represents 13 Ordinary Shares.
- F7. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.48 to $303.46, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.54 to $304.43, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $304.45 to $305.44, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $305.455 to $306.45, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.455 to $307.44, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $307.46 to $307.87, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F14. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
- F15. These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares subject to this option are subject to accelerated vesting upon a change in control or certain termination events.
- F16. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.
- F17. These securities vest over a four-year period as follows: 25% on June 30, 2018, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.
Key Figures
ADS sold: 145,861 American Depositary Shares
Shares from option exercises: 1,736,800 ordinary shares
Direct ordinary share holdings: 5,445,917 ordinary shares
+4 more
7 metrics
ADS sold
145,861 American Depositary Shares
Total open-market or private sales on July 14, 2026
Shares from option exercises
1,736,800 ordinary shares
Total underlying ordinary shares from option exercises on July 14, 2026
Direct ordinary share holdings
5,445,917 ordinary shares
Ordinary shares held directly after the reported transactions
Remaining share options
462,866 share options
Options with $7.7000 exercise price expiring 2027-09-26 remaining after partial exercise
Option exercise price
$7.7000 per ordinary share
Exercise price for options on 472,134 underlying ordinary shares
Option exercise price
$2.8400 per ordinary share
Exercise price for options on 1,264,666 underlying ordinary shares
ADS to ordinary share ratio
1 ADS : 13 ordinary shares
Each American Depositary Share represents 13 ordinary shares
Key Terms
Rule 10b5-1 trading plan, grantor retained annuity trust, American Depositary Shares, beneficial ownership, +2 more
6 terms
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
grantor retained annuity trust financial
"These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee."
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
beneficial ownership regulatory
"The beneficiaries include the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Roth IRA financial
"These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account."
A Roth IRA is a retirement savings account you fund with money that’s already been taxed, and withdrawals taken in retirement under the account rules are tax-free. It matters to investors because it shifts the tax bill to today instead of retirement, potentially increasing after-tax income later—think of it like paying for a lifetime subscription now so you can use it without extra charges in the future—helpful for long-term tax planning and flexibility.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BeOne Medicines (ONC) CEO John Oyler report?
John Oyler reported exercising share options and selling American Depositary Shares. On July 14, 2026 he exercised options covering 1,736,800 ordinary shares and sold 145,861 ADSs in open‑market transactions, combining derivative exercises with cash sales.
How many BeOne Medicines (ONC) ADSs did John Oyler sell and at what prices?
He sold a total of 145,861 American Depositary Shares. The weighted‑average sale prices for the various tranches ranged between approximately $302.48 and $307.87 per ADS, across multiple open‑market transactions on July 14, 2026.
What BeOne Medicines (ONC) holdings does John Oyler retain after these trades?
Following the reported transactions, Oyler directly holds 5,445,917 ordinary shares and 462,866 remaining share options. He also has indirect interests via several trusts and a Roth IRA, while disclaiming beneficial ownership of certain trust‑held shares.
Were John Oyler’s BeOne Medicines (ONC) sales made under a Rule 10b5-1 plan?
Yes. A footnote states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Oyler on March 10, 2026, indicating the transactions were pre‑arranged rather than opportunistic trades based on short‑term market movements.
How are John Oyler’s indirect BeOne Medicines (ONC) holdings structured?
Indirect holdings are spread across the P&O Trust, a grantor retained annuity trust, Oyler Investment LLC, and The John Oyler Legacy Trust, plus a Roth IRA. Oyler disclaims beneficial ownership of several trust‑held positions benefiting family members.
AI-generated analysis. How Rhea-AI works. Not financial advice.
